Mazdutide Peptide in Canada
Mazdutide is a 34-amino-acid lab-made version of oxyntomodulin, a natural gut hormone. Like that hormone, it acts on both glucagon and GLP-1 receptors. Labs use it as the reference compound for that two-receptor pairing. Its published phase 3 trials enrolled only Chinese adults. China approved it in 2025, and no other regulator has.

Pack prices and discount codes don't combine. You always get the bigger saving.
Sold for laboratory research use only. Not for human or veterinary use. 19+.
- Phase 3 results in NEJM, Chinese adults
- May 2025
- Modelled on oxyntomodulin
- Gut hormone
- Molar mass, per the WHO INN record
- 4563g/mol
- Receptors: glucagon and GLP-1
- 2
- Approved as a drug, since 2025
- China only
- Free over $250 Shipping $20 to $25 under that
- Interac e-Transfer Confirms in ~30 min
- 14-day returns Free return shipping
- Third-party tested Janoshik Analytical results below
- Ships cold Paid by noon, ships same day
- Mixing calculator Get your volumes
What is Mazdutide?
The plain-language version, first.
Nature got to the dual agonist first. It just never told anybody.
Here's a slightly annoying fact if you're a medicinal chemist.
Everybody has spent years building molecules that pull two receptors at once. Clever work, real engineering, genuine achievement.
Your gut has been making one since before anybody thought of it.
It's called oxyntomodulin. It comes off the same precursor protein as GLP-1, it is a perfectly ordinary human peptide, and it engages both the GLP-1 receptor and the glucagon receptor without anybody designing it to.
Mazdutide is an analogue of that.
So the job here wasn't invention. It was taking something nature already built and fixing the part nature had no reason to care about, which is how long it lasts.
Native oxyntomodulin clears in minutes. Nature is not optimising for weekly dosing.
What mazdutide is
What researchers watch it do.
Two receptors, one peptide, and no chemist required for the original draft.
Alright. Proglucagon is one precursor protein that gets cut into different pieces depending on which tissue is doing the cutting.
Cut it one way, you get glucagon. Cut it another way, you get GLP-1. Cut it a third way and you get oxyntomodulin, which happens to talk to both receptors.
Same source material. Different scissors. Completely different job.
That's a genuinely elegant bit of biology and it is also the whole basis of this molecule.
This analogue takes that natural dual-acting peptide and does the standard two things: stabilise it against the enzymes that clear it, and add a lipid so it binds albumin and sticks around.
Here's the honest part. Being derived from a human peptide sounds reassuring and it is not an argument about anything.
Plenty of things your body makes are unpleasant in the wrong amount, and a modified version of a natural molecule is still a modified molecule with its own behaviour.
Natural origin is a fact about where it came from. It is not a safety claim, and we are not making one.
What does the research say about Mazdutide?
What the studies found, and where they stand.
Approved in one country, unapproved everywhere else, and unusually easy to misread because of it.
This one is easy to misread, so here is the shape of it plainly.
It holds regulatory approval in China and nowhere else. Not Canada.
Not the United States. Not Europe.
One approval is not no approval, and it is also not the same thing as approved.
That matters for reading the literature, because a good deal of the clinical work sits with one sponsor in one jurisdiction, which is a narrower base than the multi-region programmes behind some of its neighbours on this shelf.
It is not a criticism of the work. It is a note about how much independent replication exists, which is a different question and the one people forget to ask.
Approved somewhere, unapproved here, and thinner outside its home programme than the headline suggests.
Canadian stock, cold-shipped from BC. Research use only.
What did the lab find in our Mazdutide?
2 sizes, one lot each, the lab's numbers for every one.
5 mgLot 2247-58798.27%5.05 mgOpenClose
10 mgLot 2212-67299.12%10.27 mgOpenClose
What's in a vial of Mazdutide?
The chemistry, exactly as released.
Who studies Mazdutide?
Who tends to order this one, and why.
- 1
Dual-agonist pharmacology labs
If you're characterising GCGR/GLP-1R co-agonism, mazdutide is now the reference compound, because it's the only one a regulator has ever signed off on.
- 2
Energy expenditure researchers
The glucagon arm is the part meant to move metabolic rate. That's a distinct readout from appetite suppression and it's the reason this molecule exists at all.
- 3
Liver metabolism researchers
Glucagon receptor agonism drives hepatic fat oxidation, which is why this class keeps turning up in liver fat discussions alongside the weight data.
- 4
Regulatory and market analysts
A mechanism approved in one jurisdiction and unapproved everywhere else is a rare, clean case study. Mazdutide is currently that case study.
Sold for laboratory research only. This is not guidance for personal use, and nothing here is a recommendation.
Where did Mazdutide come from?
How it got here.
Oxyntomodulin was described as a gut hormone long before anyone thought of it as a drug template. Same proglucagon gene as GLP-1, different processing, hits the glucagon receptor and the GLP-1 receptor both, and gets cleared so fast it was never going to be useful on its own.
Eli Lilly built an engineered version and gave it the internal code OXM3. On 21 August 2019 Lilly licensed the China rights to Innovent Biologics, and the molecule picked up two more names along the way: IBI362 on the Innovent side, LY3305677 on the Lilly side.
Innovent ran the GLORY programme in Chinese participants. GLORY-1 reported at 48 weeks in NEJM. GLORY-2 pushed the dose to 9 mg and reported in JAMA.
On 27 June 2025 the NMPA approved mazdutide for chronic weight management as Xinermei, and in September 2025 for type 2 diabetes.
That made it the first dual glucagon and GLP-1 receptor agonist approved anywhere in the world. Not the first in China. The first, full stop. The mechanism the entire Western pipeline has been chasing crossed the finish line in China first.
- 1
2019: Lilly hands off China
Eli Lilly licenses the China rights to its engineered oxyntomodulin analogue, internal code OXM3, to Innovent Biologics on 21 August 2019. The molecule carries two designations from then on, IBI362 and LY3305677.
- 2
2025: the GLORY data lands
GLORY-1 (n=610) reports -11.00% at 4 mg and -14.01% at 6 mg versus +0.30% on placebo at week 48 in NEJM. GLORY-2 (n=461) later reports -16.65% at 9 mg over 60 weeks in JAMA.
- 3
27 June 2025: a world first
China's NMPA approves mazdutide for chronic weight management as Xinermei, making it the first dual glucagon and GLP-1 receptor agonist approved by any regulator anywhere. Type 2 diabetes approval follows that September.
How do I buy Mazdutide in Canada?
What ships, how fast, and the paperwork.
Approved in China only. Xinermei is a real approved product in China. Mazdutide has no FDA, EMA or Health Canada authorisation, and what we ship is a research material rather than any approved drug product.
The anti-doping answer is unresolved. Mazdutide isn't named on the 2026 WADA list, but S0 catches unapproved substances and WADA hasn't said whether an NMPA approval counts. Anyone in tested sport should ask their anti-doping authority directly rather than guess.
Canadian stock, ships from BC. Held in Canada so it isn't sitting in a customs queue while the cold chain degrades. Research use only, and not for any human or veterinary application.
What else do people ask?
5 answers, none of them dodges.
What makes mazdutide different from semaglutide?
Semaglutide hits one receptor. Mazdutide hits two, the GLP-1 receptor and the glucagon receptor, because its backbone is closer to oxyntomodulin than to GLP-1. The glucagon arm is meant to add energy expenditure and hepatic fat oxidation rather than more appetite suppression. It's a different bet, not a stronger version of the same one.
Is mazdutide approved anywhere?
In China, yes. The NMPA approved it for chronic weight management on 27 June 2025 under the brand Xinermei, and for type 2 diabetes in September 2025. That was the first approval of a dual glucagon and GLP-1 receptor agonist by any regulator anywhere in the world. The FDA, EMA and Health Canada have not approved it.
Why would glucagon activity belong in a molecule like this?
Glucagon raises blood sugar, which sounds disqualifying on its own. It also raises energy expenditure and drives fat oxidation in the liver. The dual-agonist argument is that pairing it with GLP-1 lets the incretin arm handle glycaemia while the glucagon arm contributes metabolic effects that GLP-1 doesn't produce by itself.
What weight change did the trials report?
GLORY-1 randomised 610 Chinese adults and reported -11.00% at 4 mg and -14.01% at 6 mg against +0.30% on placebo at week 48 (NEJM 2025). GLORY-2 tested 9 mg in 461 Chinese adults over 60 weeks and reported -16.65% versus -1.50% (JAMA 2026). Both were run under medical supervision using pharmaceutical material.
Is mazdutide banned in sport?
It isn't named on the 2026 WADA Prohibited List. WADA's S0 category catches substances with no approval from any governmental regulatory health authority, and whether China's NMPA approval takes mazdutide out of S0 has not been publicly determined. That's an open question, not a clearance. Anyone in tested sport should confirm with their own anti-doping authority.
Mazdutide Peptide vs Tirzepatide: what's the difference?
Stacked together constantly, compared almost never.
Two dual agonists, two completely different second buttons, and the difference is the entire design argument.
Mazdutide pairs GLP-1 with the glucagon receptor, following a template nature already built in oxyntomodulin. Approved in China only.
Tirzepatide pairs GLP-1 with GIP, the receptor the field spent twenty years dismissing. Approved in Canada and the United States.
Same first receptor, opposite bets on the second. One bet has approvals on three continents and the other has one, which is worth more than any forum comparison of the two. Tirzepatide has its own page here
What pairs well with Mazdutide?
What researchers stack alongside it.
Pairing is where research gets ahead of itself. These are the compounds researchers put in the same order as Mazdutide Peptide, which is a statement about ordering habits, not about evidence. Two things in one cart have not been studied together unless somebody studied them together.

Cut six amino acids off the front of a peptide and it got roughly ten thousand times more active. That result, from 1987, is the reason this entire shelf exists.
Supplies for the lab
What else is in Metabolic?
Other compounds in the same research category.
Ready to order Mazdutide?
One last look before you decide.
Freeze-dried, lab results on the page, ships cold
You've got the file and the lab's numbers that back it, lot by lot. If that's the kind of source you were after, Mazdutide is right here.
Sold for laboratory research use only. Not for human or veterinary use, and not for human consumption. 19+. Not approved by Health Canada or any other regulatory body.
Page last updated October 13, 2026. Reviewed by the Pro Peptide team.
What do people search for with Mazdutide?
Related searches.


